ischemic heart disease ihd drugs market size, ischemic heart disease ihd drugs market growth, ischemic heart disease ihd drugs market outlook, ischemic heart disease ihd drugs market share, ischemic heart disease ihd drugs market demand, ischemic heart disease ihd drugs market cagr
How big is the ischemic heart disease (ihd) drugs market today, and what are its future growth expectations?
The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.
The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.
Get Your Free Sample of The Global Ischemic Heart Disease (IHD) Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp
How has the ischemic heart disease (ihd) drugs market evolved, and what factors have shaped its growth?
The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in 2022, according to the World Obesity Federation, the UK-based Federation that drives global efforts to reduce, prevent, and treat obesity, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.
What are the major segments of the ischemic heart disease (ihd) drugs market?
The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Order your report now for swift delivery
Which companies dominate the ischemic heart disease (ihd) drugs market?
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
How will evolving trends contribute to the growth of the ischemic heart disease (ihd) drugs market?
Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative myosin inhibitor, to gain a competitive edge in the market. A cardiac myosin inhibitor is a drug that reduces myosin activity in the heart muscle, lowering contraction force. It’s beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs heart function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, launched Camzyos (mavacamten). It is the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. The drug works as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and improving cardiac filling pressures. This helps decrease dynamic left ventricular outflow tract (LVOT) obstruction.
What are the key regional dynamics of the ischemic heart disease (ihd) drugs market, and which region leads in market share?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Ischemic Heart Disease (IHD) Drugs Market Report 2025 Offer?
The ischemic heart disease (ihd) drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13467
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
